Jade Biosciences Net Income

The latest net income for JBIO is $-190M as of June 2026. That compares with $-56M in the prior-year period — down 235.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Jade Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, JBIO's net income moved from $-56M to $-190M — a 235.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jade Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, JBIO currently prints $-190M for net income, while the sector average sits near $16B. That is roughly 101.2% below the sector mean. Large gaps often invite a closer look at Jade Biosciences's growth, margins, and balance sheet.

A net income figure of $-190M for JBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting JBIO's net income ($-190M), review year-over-year change from $-56M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.